drugset / Trial / NCT01285700
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-01
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Velmanase Alfa | Protein / enzyme biologic | 25 iu/kg | — |
| Comparator | Velmanase Alfa | Protein / enzyme biologic | 50 iu/kg | — |